

## Peroxisomal $\beta$ -oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease

Maria E. Moreno-Fernandez, ... , Kasper Hoebe, Senad Divanovic

*JCI Insight*. 2018;3(6):e93626. <https://doi.org/10.1172/jci.insight.93626>.

Research Article

Inflammation

Metabolism

Nonalcoholic fatty liver disease (NAFLD), a metabolic predisposition for development of hepatocellular carcinoma (HCC), represents a disease spectrum ranging from steatosis to steatohepatitis to cirrhosis. *Acox1*, a rate-limiting enzyme in peroxisomal fatty acid  $\beta$ -oxidation, regulates metabolism, spontaneous hepatic steatosis, and hepatocellular damage over time. However, it is unknown whether *Acox1* modulates inflammation relevant to NAFLD pathogenesis or if *Acox1*-associated metabolic and inflammatory derangements uncover and accelerate potential for NAFLD progression. Here, we show that mice with a point mutation in *Acox1* (*Acox1*<sup>Lampe1</sup>) exhibited altered cellular metabolism, modified T cell polarization, and exacerbated immune cell inflammatory potential. Further, in context of a brief obesogenic diet stress, NAFLD progression associated with *Acox1* mutation resulted in significantly accelerated and exacerbated hepatocellular damage via induction of profound histological changes in hepatocytes, hepatic inflammation, and robust upregulation of gene expression associated with HCC development. Collectively, these data demonstrate that  $\beta$ -oxidation links metabolism and immune responsiveness and that a better understanding of peroxisomal  $\beta$ -oxidation may allow for discovery of mechanisms central for NAFLD progression.

Find the latest version:

<https://jci.me/93626/pdf>



# Peroxisomal $\beta$ -oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease

Maria E. Moreno-Fernandez,<sup>1,2</sup> Daniel A. Giles,<sup>1,2,3</sup> Traci E. Stankiewicz,<sup>1,2</sup> Rachel Sheridan,<sup>1,4</sup> Rebekah Karns,<sup>1,5</sup> Monica Cappelletti,<sup>1,2</sup> Kristin Lampe,<sup>1,2</sup> Rajib Mukherjee,<sup>1,2</sup> Christian Sina,<sup>6</sup> Anthony Salles,<sup>1,7</sup> James P. Bridges,<sup>1,7</sup> Simon P. Hogan,<sup>1,8</sup> Bruce J. Aronow,<sup>1,9</sup> Kasper Hoebe,<sup>1,2</sup> and Senad Divanovic<sup>1,2</sup>

<sup>1</sup>Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. <sup>2</sup>Division of Immunobiology, Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, Ohio, USA. <sup>3</sup>Immunology Graduate Program, CCHMC, and the University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. <sup>4</sup>Division of Pathology, CCHMC, Cincinnati, Ohio, USA. <sup>5</sup>Division of Gastroenterology, Hepatology, and Nutrition, CCHMC, Cincinnati, Ohio, USA. <sup>6</sup>Molecular Gastroenterology, University Hospital Schleswig-Holstein, Campus Lübeck, Germany. <sup>7</sup>Division of Neonatology and Pulmonary Biology, <sup>8</sup>Division of Allergy and Immunology, and <sup>9</sup>Division of Biomedical Informatics, CCHMC, Cincinnati, Ohio, USA.

**Nonalcoholic fatty liver disease (NAFLD), a metabolic predisposition for development of hepatocellular carcinoma (HCC), represents a disease spectrum ranging from steatosis to steatohepatitis to cirrhosis. Acox1, a rate-limiting enzyme in peroxisomal fatty acid  $\beta$ -oxidation, regulates metabolism, spontaneous hepatic steatosis, and hepatocellular damage over time. However, it is unknown whether Acox1 modulates inflammation relevant to NAFLD pathogenesis or if Acox1-associated metabolic and inflammatory derangements uncover and accelerate potential for NAFLD progression. Here, we show that mice with a point mutation in *Acox1* (*Acox1*<sup>Lampe1</sup>) exhibited altered cellular metabolism, modified T cell polarization, and exacerbated immune cell inflammatory potential. Further, in context of a brief obesogenic diet stress, NAFLD progression associated with *Acox1* mutation resulted in significantly accelerated and exacerbated hepatocellular damage via induction of profound histological changes in hepatocytes, hepatic inflammation, and robust upregulation of gene expression associated with HCC development. Collectively, these data demonstrate that  $\beta$ -oxidation links metabolism and immune responsiveness and that a better understanding of peroxisomal  $\beta$ -oxidation may allow for discovery of mechanisms central for NAFLD progression.**

## Introduction

Nonalcoholic fatty liver disease (NAFLD), the world's most common chronic liver disorder, represents a spectrum of liver diseases ranging from benign hepatic lipid accumulation (nonalcoholic steatosis; NAFL) to inflammation and fibrosis (nonalcoholic steatohepatitis; NASH) and, potentially, hepatocellular carcinoma (HCC) (1–5). However, despite NAFLD's clinical and public health significance, the mechanisms underlying its immunopathogenesis, including those leading to HCC, remain underdefined. Thus, the discovery of novel mechanisms regulating NAFLD progression may provide novel therapeutic targets for the inhibition of NASH progression to HCC and ultimately reduce NAFLD prevalence.

Innate and adaptive immune responses are central to both NAFLD and HCC pathogenesis (4, 6). Among innate immune activators, TLR4 signaling, activated in response to endotoxin (LPS) sensing, has been associated with NAFLD progression in mice (7–9) and correlated with NAFLD severity in humans (10). Obesity-associated increased intestinal permeability and systemic endotoxemia (11) have been linked with NAFLD pathogenesis (12). Increased TLR4 activation augments hepatic and systemic cytokine production, including cytokines known to induce the differentiation and activation of Th17 cells (13). Notably, IL-17 axis activation is critical for NAFLD to NASH transition (9, 14–18).

**Authorship note:** MEMF, DAG, and TES contributed equally to this work.

**Conflict of interest:** The authors have declared that no conflict of interest exists.

**Submitted:** February 23, 2017

**Accepted:** February 8, 2018

**Published:** March 22, 2018

**Reference information:**

*JCI Insight.* 2018;3(6):e93626.

<https://doi.org/10.1172/jci.insight.93626>

insight.93626.

In addition to inflammation, hepatic cellular metabolism plays a critical role in NAFLD progression. Modulation of mitochondrial function (19) and lipolytic and lipogenic pathways in hepatocytes have profound effects on the development of steatosis (20). In fact, altered mitochondrial activity, or increased de novo lipogenesis in the liver, in parallel with steatosis, promotes cellular stress, lipid peroxidation, and induction of inflammation (21). However, while inflammatory and metabolic pathways are often causally linked with NAFLD, the pathways essential for the interaction between these biological processes in NAFLD progression are not well defined.


Acyl-coenzyme A oxidase (Acox1), a rate-limiting enzyme in the peroxisomal  $\beta$ -oxidation pathway, is responsible for catabolism of very long-chain fatty acids. Saturated long-chain fatty acids are known to activate inflammatory and innate immune responses in immune cells (22–24). Altered Acox1 function is associated with spontaneous liver damage in humans (25–27). In fact, patients with pseudoneonatal adrenoleukodystrophy, a rare inflammatory neurodegenerative disease caused by Acox1 deficiency, exhibit hepatomegaly due to impairment of peroxisomal fatty acid  $\beta$ -oxidation of very long-chain fatty acids (28). Similarly, Acox1-deficient and Acox1 mutant mice exhibit spontaneous steatosis and steatohepatitis, augmented liver regeneration, and spontaneous development of HCC around 1 year of age (26, 29). These findings suggest that Acox1, in addition to its role in metabolism, may also play an important role in regulation of inflammation via peroxisomal  $\beta$ -oxidation — something that has not been previously interrogated, to our knowledge. Thus, we hypothesized that Acox1-dependent modulation of metabolic function and inflammatory vigor in obesity would augment induction of proinflammatory immune axes and allow for accelerated and exacerbated NAFLD pathogenesis.

## Results

*Acox1-dependent peroxisomal  $\beta$ -oxidation regulates inflammatory cytokine production and T cell polarization.* The role of Acox1 in modulation of systemic inflammatory cascades in vivo, at base line, and after inflammatory challenge has not been previously defined. Hence, we quantified in vivo basal and LPS-induced systemic cytokine production in WT and Acox1<sup>Lampe1</sup> mice, which have a splice donor site mutation in the *Acox1* gene between exons 12 and 13, resulting in partial deletion of the C-terminal acyl-CoA oxidase domain (29). Acox1<sup>Lampe1</sup> mice, compared with WT controls, exhibited significantly increased basal serum IL-6 and TNF- $\alpha$  levels and trends toward increased IFN- $\gamma$  and IL-17A levels (Figure 1A). Following LPS challenge, in addition to elevated IL-6 and TNF- $\alpha$ , the serum levels of IFN- $\gamma$  and IL-17A were also significantly elevated in Acox1<sup>Lampe1</sup> mice (Figure 1B). LPS does not directly induce IL-17 production; rather, it induces production of cytokines (e.g., IL-6, IL-1 $\beta$ , and IL-12), which promote IL-17 production via polarization of Th17 cells (30) and NK cell and NKT cell activation (31–33). Accordingly, Acox1<sup>Lampe1</sup> BM-derived DCs exhibited significantly increased production of IL-6 and IL-1 $\beta$ , potential IL-17-inducing cytokines, after LPS stimulation (Figure 1C).

To test whether peroxisomal  $\beta$ -oxidation has a direct effect on CD4<sup>+</sup> T cell polarization, naive WT CD4<sup>+</sup> T cells were treated with thioridazine, a chemical inhibitor of peroxisomal  $\beta$ -oxidation, prior to being cultured under Th1 or Th17 polarizing conditions and stimulated with PMA/ionomycin. Notably, thioridazine treatment in vitro promoted both Th17 and Th1 polarization (Figure 1D) and reduced Treg polarization (data not shown). Hence, the impact of Acox1<sup>Lampe1</sup> mutation on naive CD4<sup>+</sup> T polarization was examined next. Naive CD4<sup>+</sup> T cells from Acox1<sup>Lampe1</sup> mice, cultured under Th17 and Th1 polarizing conditions, exhibited increased skewing toward the Th17 but not the Th1 phenotype compared with naive WT CD4<sup>+</sup> T cells (Figure 1, E and F). However, at baseline, Acox1<sup>Lampe1</sup> mice had similar splenic Th17, Th1, and Treg numbers (Figure 1G). These findings suggest that Acox1<sup>Lampe1</sup> mutation does not alter basal, splenic T cell composition or total numbers — rather, it alters the T cell response to a stimulus. Overall, our findings suggest that Acox1 regulates both innate and adaptive immune responsiveness and immune cell inflammatory vigor.


*Acox1-dependent peroxisomal  $\beta$ -oxidation regulates whole body metabolism and brown adipose tissue activity.* While the Acox1<sup>Lampe1</sup> mutation is associated with protection from weight gain (Supplemental Figure 1A; supplemental material available online with this article; <https://doi.org/10.1172/jci.insight.93626DS1>), whether Acox1<sup>Lampe1</sup> mutation modulates whole body metabolism has not been defined (29). Notably, despite increased food intake (Figure 2A) and similar locomotor activity (Figure 2B), Acox1<sup>Lampe1</sup> mice displayed significantly increased energy expenditure (Figure 2C) and oxygen consumption (Figure 2D) compared with WT controls. These results suggested a potential increase in brown adipose tissue-driven (BAT-driven) metabolic activity. In fact, subsequent analyses revealed that Acox1<sup>Lampe1</sup> mice exhibited a



**Figure 1. Acox1<sup>Lampe1</sup> mutation promotes proinflammatory immune responsiveness.** (A and B) Twelve-week-old, chow diet-fed, Acox1<sup>Lampe1</sup> mice and WT littermate controls were challenged i.p. with biotinylated capture Ab (20  $\mu$ g/mouse) 3 hours prior to i.v. saline (NS) or LPS challenge (25  $\mu$ g/mouse; ultrapure *E. coli* 0111:B4). Twenty-four hours later, serum was collected, and IL-6, TNF- $\alpha$ , IFN- $\gamma$ , and IL-17A levels were quantified by IVCCA ELISA. (C) Supernatant IL-6 and IL-1 $\beta$  levels from BM-derived DCs (BMDC), of chow diet-fed, Acox1<sup>Lampe1</sup> mice and WT littermate controls stimulated for 24 hours with saline (NS) or LPS (100 ng/ml). (D) Splenic naive CD4<sup>+</sup> T cells from chow diet-fed WT mice, isolated by negative selection using magnetic beads, were cultured under Th17 and Th1 polarizing conditions with or without peroxisomal  $\beta$ -oxidation inhibitor (thiordizine, 1  $\mu$ M) and the frequency of IL-17A- and IFN- $\gamma$ -expressing cells were quantified by flow cytometry. (E and F) Splenic naive CD4<sup>+</sup> T cells from 12-week-old, chow diet-fed, Acox1<sup>Lampe1</sup> mice and WT littermate controls, isolated by negative selection using magnetic beads, were cultured under Th17 and Th1 polarizing conditions, and the frequency of IL-17A- and IFN- $\gamma$ -expressing cells was quantified by flow cytometry. (G) Frequency of total splenic Th1 (CD3<sup>+</sup>CD4<sup>+</sup>IFN- $\gamma$ <sup>+</sup>IL-17A<sup>-</sup>), Th17 (CD3<sup>+</sup>CD4<sup>+</sup>IL-17A<sup>+</sup>IFN- $\gamma$ <sup>-</sup>), and Treg (CD3<sup>+</sup>CD4<sup>+</sup>FOXP3<sup>+</sup>) in chow diet-fed Acox1<sup>Lampe1</sup> mice and WT littermate controls. Data represent means  $\pm$  SEM. (A, B, and E-G) Unpaired Student's *t* test; \**P* < 0.05, \*\**P* < 0.01. (C) One-way ANOVA followed by Tukey's correction; \**P* < 0.05. White bars denote WT mice; black bars denote Acox1<sup>Lampe1</sup> mice. (A, B and D) Data combined from 2 independent experiments, *n* = 3–8/condition. (C and E) Data combined from 2 independent experiments, *n* = 7/condition. (F and G) A single experiment, *n* = 3–4/condition.

significant increase in BAT/body mass ratio (Figure 2E) and expression of uncoupling protein 1 (*Ucp1*), a key mediator of energy expenditure (34) (Figure 2F). Further, this correlated with increased mitochondrial respiration in the BAT (Figure 2G). Specifically, mitochondria from Acox1<sup>Lampe1</sup> BAT displayed increased oxygen consumption rate (OCR) after supplementation with pyruvate and malate and after uncoupling of mitochondrial respiration using carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) (Figure 2G). Of interest, during periods of increased energy expenditure, triglycerides (TGs) stored in the white adipose tissue (WAT) are degraded and released as fatty acids, via the process of lipolysis, to be utilized by BAT (35). Congruent with this observation, WAT mRNA expression of *Lipe*, *Pparg*, and *Pnpla2*, genes associated with lipolysis, was increased in Acox1<sup>Lampe1</sup> mice compared with WT controls (Supplemental Figure 1B). In sum, these differences suggest that Acox1<sup>Lampe1</sup> mutation augments whole body energy expenditure and BAT activity.

*Acox1-dependent peroxisomal  $\beta$ -oxidation regulates hepatic mitochondrial activity and inflammation.* Given that the liver plays a major role in numerous metabolic processes and that hepatic mitochondrial function is




**Figure 2. Acox1<sup>Lampe1</sup> mutation modulates whole body metabolism and brown adipose tissue activity.** (A–D) Analysis of factors contributing to differential weight gain. Twelve-week-old, chow diet-fed, Acox1<sup>Lampe1</sup> mice and WT littermate controls were placed in metabolic chambers, and (A) food intake, (B) total daily locomotor activity, (C) total daily energy expenditure (EE), and (D) total daily oxygen consumption were quantified. (E–G) Analysis of brown adipose tissue (BAT) function. Twelve-week-old, chow diet-fed, Acox1<sup>Lampe1</sup> mice and WT littermate controls were utilized for analysis of (E) BAT/body mass ratio, (F) BAT *Ucp1* mRNA expression levels, and (G) BAT mitochondrial oxygen consumption rate (OCR). Data represent means  $\pm$  SEM. (A–G) Unpaired Student's *t* test; \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001. (A–F) White bars denote WT mice; black bars denote Acox1<sup>Lampe1</sup> mice. (C) Shaded regions denote night cycle; clear regions denote day cycle. (G) White squares denote WT mice; black squares denote Acox1<sup>Lampe1</sup> mice. (A) Representative of 3 individual experiments, *n* = 4/condition. (B–G) Data combined from 2 independent experiments, *n* = 3–6/condition.

linked with hepatocellular damage (19), we next evaluated whether hepatic metabolism was altered in Acox1<sup>Lampe1</sup> mice. Initial analysis of the liver indicated that Acox1<sup>Lampe1</sup> mice displayed normal embryonic and neonatal liver histology, with evidence of hepatic steatosis at 12 weeks of age (Figure 3A). At this time, Acox1<sup>Lampe1</sup> mice also exhibited an increased liver/body mass ratio and augmented hepatic TG accumulation (Figure 3, B and C). At the cellular level, unlike in BAT, mitochondria from Acox1<sup>Lampe1</sup> hepatocytes displayed decreased OCR in response to succinate and FCCP — both responses indicative of impaired mitochondrial function (Figure 3D). This reduction in mitochondrial function inversely correlated with increased hepatic lipid peroxidation and levels of hepatocellular damage, as measured by 4-hydroxynonenal (4-HNE) and alanine transaminase (ALT) levels, respectively (Figure 3, E and F).

Congruent with exacerbated hepatocellular damage and dysregulated hepatic mitochondrial metabolism, Acox1<sup>Lampe1</sup> mice, compared with WT controls, had increased hepatic T cell and neutrophil infiltration (Figure 3G) that correlated with increased hepatic mRNA expression of chemokines *Cxcl10* and *Ccl22* (Figure 3H), previously associated with T cell infiltration and IL-17 axis activation in NAFLD (16). Of note, hepatic T cells from Acox1<sup>Lampe1</sup> mice had augmented capacity to produce IL-17A but not IFN- $\gamma$  (Supplemental Figure 2, A–D). In contrast, Acox1<sup>Lampe1</sup> mice displayed a significant decrease in the presence of hepatic Tregs (Supplemental Figure 2E). Notably, reduced hepatic Treg numbers and polarization was not observed in the spleen (Figure 1G and data not shown), possibly suggesting that the Acox1-driven hepatic milieu is critical for skewed hepatic T cell infiltration.


*Short-term obesogenic-diet challenge accelerates and exacerbates Acox1-dependent peroxisomal  $\beta$ -oxidation-driven hepatocellular damage and systemic inflammation.* At baseline, Acox1<sup>Lampe1</sup> mice exhibited significantly altered energy expenditure, hepatic metabolism and systemic and hepatic inflammation. All of these parameters



**Figure 3. Acox1<sup>Lampe1</sup> mutation alters hepatic mitochondrial activity, hepatic inflammation, and hepatocellular damage.** (A) Representative liver histology (H&E staining; 20 $\times$ ) of chow diet-fed Acox1<sup>Lampe1</sup> mice and WT littermate controls. E15; 2 weeks of age; and 12 weeks of age were analyzed. Representative hepatic H&E staining. (B–H) Characterization of liver phenotype and function in 12-week-old, chow diet-fed, Acox1<sup>Lampe1</sup> mice and WT littermate controls. (B) Liver/body mass ratio. (C) Hepatic triglyceride (TG) levels. (D) Hepatic mitochondrial OCR. (E) Hepatic 4-hydroxynonenal (4-HNE) levels. (F) Serum alanine transaminase (ALT) levels. (G) Total hepatic immune (CD45<sup>+</sup>) cell infiltration determined by flow cytometry. (H) Hepatic chemokine mRNA expression of *Cxcl10* and *Ccl22*. Data represent means  $\pm$  SEM. (B–H) Unpaired Student's *t* test; \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001. White bars denote WT mice; black bars denote Acox1<sup>Lampe1</sup> mice. (B–D) Representative of 3 individual experiments, *n* = 3/condition. (E, G, H) A single experiment, *n* = 3/condition. (F) Data combined from 2 independent experiments, *n* = 5–12/condition.

are also thought to play a significant role in obesogenic diet-induced NAFLD pathogenesis. When fed a short-term (4 weeks) high-fat high-carbohydrate diet (HFHCD), Acox1<sup>Lampe1</sup> mice exhibited increased food consumption in proportion to their body weight (Supplemental Figure 3A) but were protected from weight gain as compared with WT controls (Figure 4A). As expected, the lack of weight gain in Acox1<sup>Lampe1</sup> mice correlated with significantly decreased adiposity (Supplemental Figure 3, B–D). However, despite the protection from HFHCD-driven adiposity and weight gain, Acox1<sup>Lampe1</sup> mice fed HFHCD had significantly increased liver/body mass ratio and hepatocellular damage compared with WT controls (Figure 4, B and C). Importantly, short-term HFHCD challenge, compared with chow diet, exacerbated liver weight and hepatocellular damage only in Acox1<sup>Lampe1</sup> mice — not WT controls (Figure 4, B and C). Further, in Acox1<sup>Lampe1</sup> livers, secondary insult with HFHCD accelerated hepatocellular injury, which correlated with augmented steatosis, lobular inflammation (Figure 4D), and expression of genes associated with increase ER stress (Supplemental Figure 4).


We next examined if the increased hepatocellular damage and histological changes observed in HFHCD-fed Acox1<sup>Lampe1</sup> mice were also associated with augmented hepatic inflammation. Short-term HFHCD



**Figure 4. Short-term obesogenic-diet challenge accelerates and exacerbates *Acox1*<sup>Lampe1</sup> mutation-driven hepatocellular damage and systemic inflammation.** Eight-week-old *Acox1*<sup>Lampe1</sup> mice and WT littermate controls were fed a HFHCD or chow diet for 4 weeks. (A) Weight gain. (B) Liver/body mass ratio. (C) Serum ALT levels. (D) Representative liver histology (H&E staining; 20x). (E) Total hepatic immune (CD45<sup>+</sup>) cell infiltration determined by flow cytometry. (F) Hepatic chemokine mRNA expression of *Ccl2*, *Ccl3*, *Ccl4*, *Ccl22*, and *Cxcl10*. (G) Hepatic TG levels. (H) Hepatic lipid content measured by thin layer chromatography and visualized by primuline staining. Cholesterol ester (CE), triglyceride (TG), diacylglycerol (DAG), free cholesterol (FC), monoacylglycerol (MAG), phospholipids (polar). Data represent means ± SEM. (A, E and F) Unpaired Student's *t* test; \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001. (B, C, and G) One-way ANOVA followed by Tukey's correction; \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001. (A) White squares denote WT mice fed chow diet; white circles denote WT mice fed HFHCD; black squares denote *Acox1*<sup>Lampe1</sup> mice fed chow diet; black circles denote *Acox1*<sup>Lampe1</sup> mice fed HFHCD. (B, C, and E-G) White bars denote WT mice fed HFHCD; black bars denote *Acox1*<sup>Lampe1</sup> mice fed HFHCD. (A) Representative of 2 individual experiments, *n* = 3/condition. (B, C, F and G) Data combined from 2 independent experiments, *n* = 6–9/condition. (E and H) A single experiment, *n* = 3/condition.

feeding resulted in a robust increase in numbers of hepatic CD8<sup>+</sup> T cells, NKT cells, NK cells, DCs, myeloid cells, and neutrophils in *Acox1*<sup>Lampe1</sup> mice compared with WT littermate controls (Figure 4E). Increased hepatic immune cell infiltration further correlated with exacerbated hepatic expression of macrophage and T cell–recruiting chemokines, *Ccl2*, *Ccl3*, *Ccl4*, *Ccl22*, and *Cxcl10* (Figure 4F), and enzymes associated with ROS production (Supplemental Figure 5), known to play a role in NAFLD pathogenesis (36).

As *Acox1* plays an important role in regulation of lipid processing, and as lipid accumulation is central to NAFLD progression, hepatic accumulation of specific lipid species known to play a role in NAFLD progression was analyzed. Notably, toxic lipid accumulation is associated with both the induction of steatosis and the conversion of NAFL to NASH (37). Quantification of hepatic TG levels revealed that, despite a significant difference between *Acox1*<sup>Lampe1</sup> mice and WT controls, HFHCD — compared with chow diet — did not additively impact hepatic TG accumulation in *Acox1*<sup>Lampe1</sup> mice (Figure 4G). Additional quantification of hepatic lipid species by chromatography revealed that *Acox1*<sup>Lampe1</sup> mice, in comparison with WT




**Figure 5. *Acox1<sup>Lampe1</sup>* mutation in hematopoietic cells contributes to exacerbated hepatocellular damage and systemic inflammation during short-term obesogenic-diet challenge.** Eight- to 10-week-old WT mice were lethally irradiated and subsequently reconstituted with BM from WT or *Acox1<sup>Lampe1</sup>* mice. Following successful immunological reconstitution, mice were fed a HFHCD for 4 weeks. (A) Schematic representation. (B) Weight gain. (C) Hepatic TG levels. (D) Representative liver histology (H&E staining; 20 $\times$ ). (E) Serum ALT levels. (F) Total hepatic immune (CD45<sup>+</sup>) cell infiltration determined by flow cytometry. (G) Hepatic chemokine mRNA expression of *Ccl2*, *Ccl3*, *Ccl4*, *Ccl22*, and *Cxcl10*. (H) Frequency of hepatic CD45<sup>+</sup>TCRB<sup>+</sup>CD4<sup>+</sup> T cells producing IFN- $\gamma$ , TNF- $\alpha$ , and IL-17A. (I) Frequency of hepatic CD45<sup>+</sup>TCRB<sup>+</sup>CD8<sup>+</sup> T cells producing IFN- $\gamma$  and TNF- $\alpha$ . (J) Mice were challenged i.p. with biotinylated capture Ab (20  $\mu$ g/mouse) for 3 hours, and serum IL-6, TNF- $\alpha$ , IFN- $\gamma$ , and IL-17A levels were quantified by IVCCA ELISA. Data represent means  $\pm$  SEM. (B–J) Unpaired Student’s *t* test; \**P* < 0.05, \*\**P* < 0.01. A single experiment, *n* = 5–6/condition.

controls, displayed a robust hepatic accumulation of diacylglycerol (DAG), free cholesterol (FC), monoacylglycerol (MAG), and TG at baseline — lipids all known to promote NAFLD pathogenesis (37). However, despite significantly exacerbated hepatocellular damage and inflammatory capacity, HFHCD feeding of *Acox1<sup>Lampe1</sup>* mice did not exhibit exacerbated toxic lipid accumulation in the liver (Figure 4H). Further, *Acox1<sup>Lampe1</sup>* mice fed HFHCD displayed similar hepatic *Srebp1c* mRNA expression but decreased hepatic *Ppara* mRNA expression — genes associated with fatty acid oxidation (FAO; Supplemental Figure 6). In sum, these findings suggest that both lipid metabolism and inflammation play a significant, synergistic role in hepatocellular damage and that *Acox1<sup>Lampe1</sup>* mutation likely works via augmentation of pathways alternate to *Ppara* mRNA expression. However, whether *Acox1* function in hepatocytes, or in immune cells, is the main driver of the observed phenotype is underdefined.

*Hematopoietic cell Acox1-dependent peroxisomal  $\beta$ -oxidation contributes to exacerbated hepatocellular damage and systemic inflammation.* To define whether hematopoietic or nonhematopoietic *Acox1* expression is the key contributor to exacerbated inflammation and hepatic disease, BM transfer experiments were performed (Figure 5A). WT or *Acox1<sup>Lampe1</sup>* BM was transferred into irradiated WT mice, and following successful immunological






**Figure 6. *Acox1*<sup>Lampe1</sup> mutation in hematopoietic cells alters immune responsiveness to secondary inflammatory challenge during short-term obesogen-diet challenge.** Eight- to 10-week-old WT mice were lethally irradiated and subsequently reconstituted with BM from WT or *Acox1*<sup>Lampe1</sup> mice. Following successful immunological reconstitution, mice were fed a HFHCD for 4 weeks and challenged with LPS. (A) Mice were challenged i.p. with biotinylated capture Ab (20  $\mu$ g/mouse) 3 hours prior to i.v. LPS challenge (25  $\mu$ g/mouse; ultrapure *E. coli* 0111:B4). Twenty-four hours later, serum was collected, and IL-6, TNF- $\alpha$ , IFN- $\gamma$ , and IL-17A levels were quantified by IVCCA ELISA. (B) Serum ALT levels. (C) Total hepatic immune (CD45<sup>+</sup>) cell infiltration determined by flow cytometry. (D) Hepatic chemokine mRNA expression of *Ccl2*, *Ccl3*, *Ccl4*, *Ccl22*, and *Cxcl10*. (E) Frequency of hepatic CD45<sup>+</sup>TCR $\beta$ <sup>+</sup>CD4<sup>+</sup> T cells producing IFN- $\gamma$ , TNF- $\alpha$ , and IL-17A. (F) Frequency of hepatic CD45<sup>+</sup>TCR $\beta$ <sup>+</sup>CD8<sup>+</sup> T cells producing IFN- $\gamma$  and TNF- $\alpha$ . Data represent means  $\pm$  SEM. (A–F) Unpaired Student's *t* test; \**P* < 0.05, \*\**P* < 0.01. A single experiment, *n* = 5–6/condition.

reconstitution, mice were fed a HFHCD for 4 weeks. *Acox1*<sup>Lampe1</sup> mutation in the hematopoietic compartment did not alter HFHCD-driven weight gain (Figure 5B), but — in contrast to full body mutation — it negatively impacted food intake (Supplemental Figure 7A). As expected, the similarity in body weight gain correlated with comparable hepatic TG accumulation and histological manifestations (Figure 5, C and D). In contrast, the *Acox1*<sup>Lampe1</sup> mutation in the hematopoietic compartment was sufficient to exacerbate hepatocellular damage (Figure 5E). However, the level of hepatocellular damage was blunted compared with total body *Acox1*<sup>Lampe1</sup> mice fed a HFHCD (Supplemental Figure 7B). Further, *Acox1*<sup>Lampe1</sup> mutation in the hematopoietic compartment resulted in a robust increase in the hepatic numbers of NK cells, myeloid cells, and macrophages (Figure 5F), which correlated with a modest increase in hepatic expression of macrophage-recruiting chemokines, *Ccl2*, *Ccl3*, *Ccl4*, *Ccl22*, and *Cxcl10* (Figure 5G), known to play a role in NAFLD pathogenesis (36). PMA/ionomycin stimulation of hepatic infiltrating immune cells isolated from HFHCD-fed WT mice that received *Acox1*<sup>Lampe1</sup> BM revealed increased IFN- $\gamma$ , TNF- $\alpha$ , and IL-17A production by CD4<sup>+</sup> and CD8<sup>+</sup> T cells (Figure 5, H and I), compared with CD4<sup>+</sup> and CD8<sup>+</sup> T cells isolated from WT mice that received WT BM. Transfer of *Acox1*<sup>Lampe1</sup> BM did not impact systemic proinflammatory cytokine levels (Figure 5J). These data support observations depicted in Supplemental Figure 1 and suggest that baseline differences in food intake and systemic inflammatory phenotype seen in the total body *Acox1*<sup>Lampe1</sup> mice arise from a nonhematopoietic compartment. However, these data also indicated that *Acox1*<sup>Lampe1</sup>-dependent peroxisomal  $\beta$ -oxidation in the hematopoietic compartment impacts immune cell responsiveness, which is, at least in part, responsible for the observed hepatic immune cell infiltration and augmented hepatocellular damage.

Inflammatory mediators play a role in delivering a “second hit” during NAFL to NASH transition (38), and our data (Figure 1) suggest that *Acox1*<sup>Lampe1</sup> mice exhibit significantly increased proinflammatory cytokine production following inflammatory challenge. Hence, we next examined the contribution of hematopoietic *Acox1*<sup>Lampe1</sup> mutation on immune responsiveness following inflammatory challenge. Notably, as metabolic endotoxemia (LPS levels) directly correlates with obesity and NAFLD progression, we employed



**Figure 7. Coupling of Acox1<sup>Lampe1</sup> mutation with obesogenic diet stress amplifies biological pathways associated with HCC development.** Eight-week-old Acox1<sup>Lampe1</sup> mice and WT littermate controls were fed a HFHCD or chow diet for 4 weeks. **(A)** Genes upregulated at least 2-fold in the liver of mice fed chow or HFHCD, as determined by RNA-seq. **(B and C)** Upregulated gene expression pathways determined from RNA-seq analysis. **(D and E)** Hepatic mRNA expression of genes associated with HCC development: *H19* and *Afp*. Data represent means ± SEM. One-way ANOVA with Tukey's correction; \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001. White bars denote WT mice; black bars denote Acox1<sup>Lampe1</sup> mice. **(A–C)** A single experiment, *n* = 3/condition. **(D and E)** Data combined from 2 independent experiments, *n* = 3–6/condition.

LPS challenge as a measurement of inducible inflammatory responses in the context of altered peroxisomal β-oxidation. Specifically, following LPS challenge of HFHCD-fed mice, Acox1<sup>Lampe1</sup> mutation in the hematopoietic compartment resulted in significantly increased systemic proinflammatory cytokine levels (e.g., IL-6, IFN-γ, TNF-α, and IL-17A) compared with WT controls (Figure 6A). In fact, the increase in proinflammatory cytokine levels in response to LPS challenge was comparable between hematopoietic and total body Acox1<sup>Lampe1</sup> (Figure 1B). The robust exacerbation of inflammatory vigor in mice with hematopoietic Acox1<sup>Lampe1</sup> mutation positively correlated with exacerbated hepatocellular damage (Figure 6B), significantly increasing frequency of hepatic myeloid cells (Figure 6C) and hepatic expression of immune cell–recruiting chemokines, *Ccl2*, *Ccl3*, *Ccl4*, *Ccl22* and *Cxcl10*, (Figure 6D) known to play a role in NAFLD pathogenesis (36). Further, under such experimental conditions, hematopoietic Acox1<sup>Lampe1</sup> mutation significantly augmented cytokine production (e.g., IFN-γ, TNF-α, and IL-17A) by hepatic CD4<sup>+</sup> and CD8<sup>+</sup> T cells (Figure 6, E and F). These data suggest that Acox1 expression in immune cells contributes to the phenotype seen in total body Acox1<sup>Lampe1</sup> mice. However, the lack of a significant increase in potentially toxic hepatic lipids, which may render hepatocytes susceptible to parallel/sequential inflammatory insult, due to normal Acox1 expression in hepatocytes may contribute to the cumulatively blunted liver phenotype. In sum, these findings suggest that both lipid metabolism and inflammation play a significant, synergistic role in hepatocellular damage and that Acox1 function may represent a critical link between the 2 biological processes.

**Table 1. Inflammatory gene expression profile**

Gene name	WT Chow	Acox1 <sup>Lampe1</sup> Chow	WT HFHCD	Acox1 <sup>Lampe1</sup> HFHCD
Myh9	-0.1346309	0.16716818	-0.15505389	0.85636038
Impdh1	-0.6260167	0.58145115	-0.79414495	1.35889983
Src	-0.2987529	0.45205477	-0.48376556	1.52309763
Blnk	-0.1724222	0.38219809	-0.29333647	1.39763156
Wnt4	-0.3810309	0.68577273	-0.48122584	2.35946026
Adam10	-0.3479764	0.12384446	-0.13074159	1.03216266
Itgb1	-0.0506399	0.05059524	-0.09931059	0.71143298
Nedd4	-0.1422822	-0.05850132	-0.01280562	0.63172944
Mmp14	-0.2995598	0.33620854	-0.19587051	1.22671773
Plscr1	-0.8503685	0.07437527	-0.23113493	0.83328149
Vcam1	-0.6848598	0.43154088	-0.61004383	1.15194910
Nck2	-0.2772123	0.35639047	-0.39812656	1.34628143
Tgfb1	-0.3469901	0.19122950	-0.30036834	0.86462983
Cd24a	-0.4470142	0.26633266	-0.75986282	2.76108700
Pak1	-0.0399595	0.14922694	-0.16087373	1.54336803
Ctnnb1	-0.1238585	0.00137480	-0.03938977	0.71328783
Tpd52	-0.0786054	0.04529651	-0.29542914	0.63384280
Src	-0.2987529	0.45205477	-0.48376556	1.52309763
Nck2	-0.2772123	0.35639047	-0.39812656	1.34628143
Apoa4	-2.4568108	-0.49331377	1.16073431	0.90706856
Hexb	-0.7666819	0.09066806	-0.16793594	0.45346571
Cltc	-0.2776391	0.17313110	-0.12056473	1.07601804
Pgm3	-0.8516427	-0.17543888	0.22783660	0.48628203
Bgn	-0.2969754	0.18539341	-0.19009725	0.82324901
Mfge8	-1.0420128	0.98782893	-1.13939663	2.65262746
F11r	-0.0552529	0.08616586	-0.18524730	0.71923975
Fads2,Fads3	-1.0322316	0.03144979	0.22165918	0.86638417
Wdr1	-0.2451005	0.22601914	-0.16957155	0.99662623
Mmp14	-0.2995598	0.33620854	-0.19587051	1.22671773
Ostm1	-0.2412083	0.00128038	0.00628435	0.72457758
Sptlc2	-0.5483389	0.27788807	-0.32748935	1.03165976
Apcs	-1.3612599	1.23671793	-1.12512785	2.07820583
Lama5	-0.1681831	0.20035962	-0.28909739	0.89782652
App	-1.2004269	1.03801371	-1.42755710	2.31954796
Lgals3bp	-0.2785273	0.26583234	-0.19316927	1.09798543
Smtn	-0.7043511	0.70871759	-0.54271240	2.16007753
Postn	-0.3915290	0.35489360	-0.51678244	1.26782973
Arhgdia	-0.3239098	0.31779345	-0.75478371	1.09360423
Limk2	-0.5152513	0.39448650	-0.34564380	1.14098363
Ppt1	-0.2767978	0.13099881	-0.28226657	0.73920524
Slpi	-0.0658529	0.49996964	-0.18676718	3.01679460
Il1rn	-0.5307926	0.66538115	-0.65170689	1.47008440
Large	-0.6121703	0.75539712	-0.71033915	1.34940203

The values depicted in the table represent FPKM that was log<sub>2</sub>-transformed and DESeq normalized with a subsequent baseline to the median of all samples.

*Coupling of altered Acox1-dependent peroxisomal  $\beta$ -oxidation and obesogenic diet stress amplifies biological pathways that correlate with HCC development.* To assess the preclinical relevance of exacerbated and accelerated hepatocellular damage and histological changes observed in Acox1<sup>Lampe1</sup> mice fed HFHCD, an unbiased analysis of hepatic gene expression was performed. Both genetic (Acox1<sup>Lampe1</sup> vs. WT) and dietary (chow vs. HFHCD) perturbations drove differential hepatic gene expression (Figure 7A). In fact, the combination of Acox1<sup>Lampe1</sup> mice and HFHCD feeding resulted in the highest number of significant, differentially expressed hepatic genes compared with WT chow-fed mice (Figure 7A). Comprehensive analysis of gene expression profiles, central to biological processes known to be associated with NAFLD progression,

Table 2. HCC gene expression profile


Gene name	WT Chow	Acox1 <sup>Lampe1</sup> Chow	WT HFHCD	Acox1 <sup>Lampe1</sup> HFHCD
Sparc	-0.37334001	0.01784368	-0.36941851	1.02832958
Rragd	-0.70633943	0.70624240	-0.82725365	1.88631870
Fads2,Fads3	-1.03223162	0.03144979	0.22165918	0.86638417
Aldh18a1	-0.04494412	0.20334362	-0.16585834	1.35474090
Pygb	-0.04494412	0.14563695	-0.16585834	2.13032336
Gpnmb	-0.93619023	1.29037643	-1.05710443	2.72984643
Vat1	-0.19864336	0.16149036	-0.35736051	0.81060228
Tmem136	-0.06923564	0.27726523	-0.19014986	1.27188440
Tcea1	-0.14469214	0.08054634	-0.03783571	0.68285437
Npm1	0.02577447	0.08310175	-0.25370431	1.00535096
Ostm1	-0.24120836	0.00128038	0.00628435	0.72457758
Rgs5	-0.58257285	0.13093245	-0.09301507	1.12801485
Tubb5	-0.03734866	0.09259502	-0.15663115	0.78846518
Rcn2	-0.23645118	0.12921774	-0.33049786	1.43263973
Lcn2	-2.23931443	0.86109296	-1.03621593	2.76666606
Mospd1	-0.33814014	0.35235673	-0.34090643	1.02492161
Arf3	-0.15354009	-0.00801901	-0.11182598	0.60642280
Rhoq	-0.81972486	0.53472050	-0.87622980	1.27235923
Igf2bp3	-0.04494412	0.11427724	-0.16585834	1.48739853
Ptp4a3	-1.08941423	1.13191259	-1.02820739	1.75349103
Cd24a	-0.44701429	0.26633266	-0.75986282	2.76108700
Pak1	-0.03995950	0.14922694	-0.16087373	1.54336803
Pea15a	-0.28182208	0.40904704	-0.37542050	1.00232116
Tpd52	-0.07860549	0.04529651	-0.29542914	0.63384280
Cdk4	-0.24135879	0.17196627	-0.26134399	0.79829000
Unc5b	-0.41033275	0.56958127	-0.53124697	2.07428993
Fabp4	-0.78294690	0.56886557	-0.60959572	1.95362430
Nid1	-0.17944804	0.52544808	-0.12170652	2.23595696
Ddr1	-0.69992943	0.83637678	-0.82084365	1.71344506
Psat1	-0.79058203	1.44402766	-0.91149625	3.91984256
Itih5	-0.10911154	0.11397826	-0.29212220	1.19341590
Gyg1	-0.54289431	0.44143949	-0.55064430	1.27139996
Slpi	-0.06585295	0.49996964	-0.18676718	3.01679460
Pck2	-0.27260609	0.34827939	-0.39352031	1.32943753
H19	-0.04494412	0.16956566	-0.16585834	3.40256830
Afp	-0.13134539	-0.22880899	0.18117988	0.97070386

The values depicted in the table represent FPKM that was log<sub>2</sub>-transformed and DESeq normalized with a subsequent baseline to the median of all samples.

revealed that HFHCD feeding of Acox1<sup>Lampe1</sup> mice led to a significant increase in expression of genes associated with inflammatory responses, leukocyte activation, and leukocyte adhesion (Figure 7B and Table 1). These findings are supported by our observed increase in hepatic immune cell infiltration and chemokine expression (Figure 4, E and F).

Chronic inflammation and mitochondrial dysfunction have been shown to promote tumorigenesis (39, 40). In fact, NAFLD and its related inflammation are associated with increased susceptibility for HCC development in humans (41, 42). However, mouse models of NAFLD have largely failed to encompass the full spectrum of human HCC development. Previous studies have shown that Acox1<sup>Lampe1</sup> mice spontaneously develop HCC after 1 year of age (29). Thus, we hypothesized that short-term HFHCD feeding coupled with whole body Acox1<sup>Lampe1</sup> mutation would allow for accelerated and exacerbated expression of genes associated with HCC development.

Although 4 weeks of HFHCD did not induce full-blown HCC, such short-term obesogenic diet feeding allowed for the robust induction of multiple genes associated with HCC. In fact, the expression of over 35 genes associated with HCC development in both murine models and humans were dramatically increased in young Acox1<sup>Lampe1</sup> mice fed short-term HFHCD (Figure 7C and Table 2) — a finding further validated



**Figure 8. Coupling of *Acox1<sup>Lampe1</sup>* mutation with obesogenic diet stress accelerates hepatic injury and expression of genes associated with HCC development.** Eight-week-old *Acox1<sup>Lampe1</sup>* mice and WT littermate controls were fed a HFHCD or chow diet for 4 weeks (young) and compared with *Acox1<sup>Lampe1</sup>* mice fed chow diet for 59 weeks (old). (A–E) Hepatic mRNA expression of genes associated with HCC development; *H19*, *Afp*, *Igfbp1*, *Fabp5*, and *Spp1*. (F) Upper panel: Representative liver histology (H&E staining; 20×) of the temporal evolution (8, 12, 16, 23, and 59 weeks of age) and histopathological changes in chow-fed *Acox1<sup>Lampe1</sup>* mice. *Acox1<sup>Lampe1</sup>* mice display steatosis, increasing inflammation, and liver cell injury over time with development of hepatocellular tumors at 59 weeks of age. Lower panel: Representative liver histology (H&E staining; 20×) of 12-week-old (young) *Acox1<sup>Lampe1</sup>* and WT mice fed a HFHCD. *Acox1<sup>Lampe1</sup>* mice display steatosis, inflammation, and liver cell injury after 4 weeks of HFHCD feeding. PT depicts portal tract; arrowhead depicts mitotic hepatocytes. Data represent mean ± SEM. One-way ANOVA with Tukey's correction; \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ . White bars denote WT mice fed chow diet; gray bars denote old *Acox1<sup>Lampe1</sup>* mice fed chow diet; black bars denote young *Acox1<sup>Lampe1</sup>* mice fed HFHCD. A single experiment,  $n = 3$ /condition.

by quantitative PCR (qPCR) expression of selected genes (e.g., *H19*, *Afp*, *Igfb1*, *Fabp5*, and *Spp1*) (Figure 7, D and E, and Supplemental Figure 8). Notably, hepatic levels of *H19*, an oncogene associated with HCC development, and  $\alpha$ -fetoprotein (*Afp*), a biomarker used for the diagnosis of human HCC (43) were expressed at significantly higher levels only in young *Acox1<sup>Lampe1</sup>* mice fed a short-term HFHCD (Figure 7, D and E). These data demonstrate that, in addition to exacerbated inflammatory potential and systemic and hepatic inflammation, *Acox1<sup>Lampe1</sup>* mice challenged with short-term HFHCD stress exhibit significant hepatic gene expression profiles associated with the induction of HCC.

We next compared the amplitude of hepatic inflammation and HCC-related gene expression between short-term HFHCD diet stress in young, *Acox1<sup>Lampe1</sup>* mice and aged (1-year-old) *Acox1<sup>Lampe1</sup>* mice fed a chow diet. This approach allowed us to determine whether similar pathways were upregulated under these independent conditions and whether amplitude of gene expression correlated with the observed development of tumors in aged mice. Similar to HFHCD *Acox1<sup>Lampe1</sup>* young mice, tumor-bearing, 1-year-old, *Acox1<sup>Lampe1</sup>* mice exhibited increased hepatic chemokine expression (e.g., *Ccl2*, *Ccl3*, *Ccl4*, *Ccl22*, and *Cxcl10*; Supplemental Figure 9). Further, although HFHCD feeding robustly induced expression of genes considered markers

of HCC (e.g., *H19*, *Afp*, *Igfbp1*, *Fabp5*, and *Spp1*) in young *Acox1*<sup>Lampe1</sup> mice, the expression of such genes was predominantly higher in chow-fed, aged *Acox1*<sup>Lampe1</sup> mice (Figure 8, A–E) — mice that develop hepatic tumors. The temporal evolution of histopathological changes that occur in the liver at different time points demonstrated that *Acox1*<sup>Lampe1</sup> mice display steatosis, increasing inflammation and liver cell injury as they age, with development of hepatocellular tumors at 59 weeks of age (Figure 8F, upper panel). Indeed, at 12 weeks, HFHCD-fed *Acox1*<sup>Lampe1</sup> mice displayed accelerated liver cell damage and steatosis, equivalent to a 23-week-old *Acox1*<sup>Lampe1</sup> mouse on a regular diet (Figure 8F, lower panel). Thus, utility of young *Acox1*<sup>Lampe1</sup> mice under obesogenic diet stress may allow for accelerated analysis of pathways underlying the interplay between metabolism and inflammation in obesity-driven NAFLD to HCC transition. Notably, such an approach may allow for faster, more efficacious future discovery of mechanisms that regulate NAFLD progression and pathogenesis.

## Discussion

Here, we demonstrate that *Acox1* regulates both cellular and whole body metabolism, immune cell polarization, and inflammation and that the interplay between these biological processes correlates with increased hepatocellular damage and impaired hepatic mitochondrial function. Notably, increased hepatic inflammation observed at baseline is exacerbated by HFHCD-driven metabolic burden and linked to augmented expression of HCC-related genes. In sum, our findings suggest that *Acox1*<sup>Lampe1</sup> mice coupled with obesogenic diet stress provide a relevant experimental model, encompassing both metabolism and inflammation, for induction of accelerated and exacerbated NAFLD progression and induction of HCC-related genes.

Our data demonstrate an important role for peroxisomal  $\beta$ -oxidation in regulation of whole body energy expenditure and end-organ mitochondrial function. In the context of *Acox1*<sup>Lampe1</sup> mutation, the unmetabolized substrates of this enzyme (very long-chain fatty acyl-CoAs), function as endogenous ligands for the lipid-sensing nuclear receptor *Ppara* to upregulate mitochondrial, peroxisomal, and microsomal FAO systems (44–46). Thus, the sustained increase in FAO, resulting from *Acox1* deficiency, could influence *Ppara* function and regulate energy metabolism and body weight via regulation of *Ucp1* activation in BAT (47). However, despite the possible advantages of *Acox1* deficiency in terms of weight gain, compounded adverse effects prevail in the context of end-organ sequelae and, specifically, liver pathology (48). *Acox1*<sup>Lampe1</sup> mice exhibited similar expression levels of *Ppara* after short-term HFHCD feeding compared with chow-fed counterparts. These data suggest that other pathways, in addition to *Ppara*, may be involved in the induction of genes associated with HCC in this model.

While we have demonstrated a role for *Acox1* in immune function, the underlying mechanisms of *Acox1*-dependent modulation of inflammation require further exploration. Specifically, a role for *Acox1* in inflammation has only been previously described in human fibroblasts from a patient with a mutation in the *Acox1* gene (25). *Acox1* deficiency in these cells was associated with significant alterations in the inflammatory response, leading to the activation of the IL-1 pathway and the induction of both IL-6 and IL-8 cytokines (25). Importantly, both IL-1 $\beta$  and IL-6 promote T cell polarization (49). In fact, our data demonstrated that *Acox1* function particularly and profoundly impacted Th17 cell polarization in vivo and in vitro, and it impacted the ability of Th17 cells for multicytokine production, including IFN- $\gamma$  and IL-17A secretion. Notably, systemic LPS levels, IL-17 levels, and IFN- $\gamma$  levels correlate with NAFLD progression (12, 14, 16, 50, 51), and Th17 cells have been shown to play an important pathogenic role in NAFLD-to-HCC progression (52). The fact that we observed an increase in IFN- $\gamma$  and IL-17 using chemical inhibition of peroxisomal  $\beta$ -oxidation suggested an intrinsic CD4<sup>+</sup> T helper bias. Notably, however, *Acox1*<sup>Lampe1</sup> mutation in naive CD4<sup>+</sup> T cells, compared with WT T cells, selectively promoted higher Th17 polarization compared with WT naive CD4<sup>+</sup> T cells. These data suggest that (i) thioridazine may have off-target effects; (ii) the increased Th1 responses in *Acox1* mice may not be T cell intrinsic and may be associated with increased proinflammatory potential of antigen-presenting cells; and (iii) the source of high levels of IFN- $\gamma$  in the *Acox1*<sup>Lampe1</sup> mice could also be from other immune cells, including NK and CD8<sup>+</sup> T cells. While, the role of fatty acid oxidation (FAO) through the mitochondrial  $\beta$ -oxidation pathway has previously been shown to play a role in Th17 cell polarization, our study shows for the first time to our knowledge an important role for peroxisomal  $\beta$ -oxidation in Th17 cell polarization. Nonetheless, the molecular mechanisms that link functional Th17 cell differentiation to FAO remain poorly defined. FAO has been shown to be one of the main pathways to fuel oxidative phosphorylation, which in turn fuels glycolysis, fast proliferative response, and proinflammatory cytokine production by memory CD8<sup>+</sup> T cells (53). These studies indicate that the proper regulation of intracellular lipid metabolism

is critical for T cell responses. Although future studies utilizing cell-specific deletion of *Acox1* are needed, our current findings suggest that better understanding of peroxisomal  $\beta$ -oxidation in Th17 polarization may lead to the identification of novel mechanisms by which metabolism and inflammation are coregulated and contribute to NAFLD progression.

Of note, while our work demonstrates that peroxisomal  $\beta$ -oxidation regulates immune responses, whether immune responses regulate NAFLD-associated metabolic processes remains to be fully elucidated. Interestingly, the role of IL-17 in NAFLD may not be limited simply to inflammation. In fact, IL-17 has been shown to alter metabolic processes, including adipogenesis via activation of Kruppel-like factors (54). Further, we have previously demonstrated that IL-17RA-deficient mice exhibit significantly increased steatosis (14). Therefore, whether the IL-17 axis regulates peroxisomal  $\beta$ -oxidation and subsequent hepatic lipid accumulation, and the mechanisms underlying this potential effect, is an important question moving forward.

We also demonstrate that *Acox1*<sup>Lampe1</sup> mice fed HFHCD develop accelerated and exacerbated hepatocellular damage — something that uncoupled lipid toxicity from inflammation during obesogenic diet feeding. Although the hepatic accumulation of toxic lipids in *Acox1*<sup>Lampe1</sup> mice was dependent on *Acox1* function, it was found to be independent of dietary intake. Further, to define whether *Acox1* expression by hematopoietic or nonhematopoietic cells was central to the exacerbated inflammation and hepatic disease, BM transfer experiments were performed. WT mice reconstituted with *Acox1*<sup>Lampe1</sup> BM fed a HFHCD displayed augmented inflammation and hepatocellular damage. However, the severity of hepatocellular damage was blunted in comparison with the levels observed in nonirradiated, total body *Acox1*<sup>Lampe1</sup> mice fed a HFHCD. These data suggest that hematopoietic *Acox1* expression plays an important role in the inflammatory phenotype seen in *Acox1*<sup>Lampe1</sup> mice. However, these data also suggest that such effects alone are not sufficient to drive differential development of hepatic steatosis or fully alter the severity of hepatocellular damage. This effect could be partially due to the short duration of HFHCD feeding (4 weeks) — something that precludes robust hepatic triglyceride accumulation in WT animals as compared with *Acox1*<sup>Lampe1</sup> mice.

Specifically, increased hepatic triglyceride synthesis and storage represents the “first hit” in NAFLD and renders the hepatocytes susceptible to parallel/sequential inflammatory hits, potential cell death, and disease progression. Endotoxemia, oxidative stress, cytokine production, and other proinflammatory mediators have all been shown to play roles in delivering a “second hit” during the transition from simple steatosis to NASH (38). As hepatic inflammation is one of the most distinguished features of NASH, hepatic immune responses may also play critical roles in the pathogenesis of NASH. In fact, exogenous administration of an inflammatory stimuli to WT mice reconstituted with *Acox1*<sup>Lampe1</sup> BM and fed a HFHCD exacerbated hepatocellular damage, as compared with WT mice reconstituted with WT BM. These data suggest that, in mice with impaired hematopoietic peroxisomal  $\beta$ -oxidation (e.g., *Acox1*<sup>Lampe1</sup> mice), the intrinsic immune cell inflammatory potential might further contribute to the “second hit” stress-mediated damage and NAFLD progression to HCC. In fact, the utility of our model may allow for definition of the metabolic processes that regulate inflammatory potential and the complex interactions between inflammation and lipid deposition/toxicity in NAFLD progression. However, specific experiments involving *Acox1*-conditional KO mice will be necessary for determination of the critical cell types and pathways regulating peroxisomal  $\beta$ -oxidation in NAFLD progression.

Taken together, our data provide potentially novel insights into the interactions of metabolism and inflammation in the pathogenesis of NAFLD progression. Overall, our findings suggest that coupling of genetic and dietary stress significantly augments inflammatory vigor, accelerates and exacerbates NAFLD, and promotes induction of HCC-associated genes — something possibly dependent on exacerbated immune activation and impaired fatty acid  $\beta$ -oxidation. Additionally, the introduction of short-term HFHCD feeding in the context of *Acox1* deficiency induces expression of HCC genes that normally take more than a year to develop in the absence of dietary challenge.

## Methods

*Mice.* *Acox1*<sup>Lampe1</sup> mice on a C57BL/6 background were generated as previously described (29) and were matched for nicotinamide nucleotide transhydrogenase (*Nnt*) mutation status (55). Animals were housed in a specific pathogen-free animal facility at CCHMC and handled in high-efficiency particulate-filtered laminar flow hoods with free access to food and water. For all studies, littermate WT and *Acox1*<sup>Lampe1</sup> heterozygous or homozygous mice derived from *Acox1*<sup>Lampe1</sup> heterozygous parents were utilized.

*Dietary modulation.* Mice were fed either regular chow (fat 13.5% kcal, carbohydrate 59% kcal, protein 27.5% kcal; LabDiet 5010) or a HFHCD (fat 58% kcal, carbohydrate 25.5% kcal, protein 16.4% kcal; Research Diets, catalog D12331; plus carbohydrates in drinking water [55 mM sucrose + 128 mM fructose]; refs. 14, 56). For all studies, body weight and food consumption were quantified weekly.

*BM transfer.* BM chimeric mice were generated using 8-week-old WT recipient mice. Briefly, recipient mice were conditioned by whole body irradiation and were reconstituted via tail vein injection of  $1 \times 10^6$  BM cells derived from femurs of WT or Acox1<sup>Lamp1</sup> mice. Peripheral blood chimerism was assessed by flow cytometric analysis 8 weeks after BM reconstitution. Following successful BM reconstitution, mice were placed on chow or HFHCD as described above.

*Hepatic function and phenotyping.* Hepatic TGs were quantified using Triglyceride Reagent and Triglyceride Standards (Pointe Scientific). Serum ALT levels were quantified using ALT Reagent and Catatrol I and II (Catachem). Lipid peroxidation was quantified using 4-HNE ELISA reagents (Cell Biolabs) as previously described (16). For histology, liver tissue was fixed in 10% buffered formalin, stained with H&E, and evaluated by a board-certified pathologist. Hepatic immune infiltration was quantified by flow cytometry of single cell suspensions following hepatic digestion as previously described (14, 16). All antibodies used were from eBioscience.

*Quantification of cytokine levels.* For quantification of in vivo cytokine production, in vivo cytokine capture assay (IVCCA) was employed as previously described. Briefly, biotinylated capture antibodies to IL-6 (MP5-32C11, catalog 36-7062-85), TNF- $\alpha$  (TN3, catalog 36-7423-85), IFN- $\gamma$  (R4-6A2, catalog 36-7312-85), and IL-17A (eBio17B7, catalog 13-7177-85) (all from eBioscience) were injected i.p., and terminal serum collection was performed 24 hours later (9, 14, 16, 57, 58). Further, for quantification of LPS-driven cytokine production in vivo, mice were injected i.p. 3 hours prior to LPS (25  $\mu$ g/mouse) challenge, and serum cytokine levels were determined 24 hours later. For in vitro cytokine production, IL-6 and IL-1 $\beta$  ELISAs (BD Biosciences) were utilized according to the manufacturer's instruction.

*T cell polarization.* Naive CD4<sup>+</sup> T cells were isolated from the spleen and cultured using anti-CD3/CD28 (catalog 14-0031-82 and catalog 14-0281-81, respectively; 1  $\mu$ g/ml and 0.5  $\mu$ g/ml, respectively), in DMEM supplemented with FBS, nonessential amino acids, and vitamins. Polarization of naive CD4<sup>+</sup> T cell to Th17, Th1, or Tregs was achieved via supplementation of culture media for 6 days. Th17 skewing was induced by supplementation of culture media with TGFB (1 ng/ml), IL-6 (10 ng/ml), IL-23 (20 ng/ml), and IL-1 $\beta$  (1 ng/ml). Th1 skewing was induced by supplementation of culture media with IL-12 (20 ng/ml). Treg skewing was induced by supplementation of culture media with TGFB (10 ng/ml) and IL-2 (100 U/ml). All recombinant proteins and antibodies were from eBioscience.

*Mitochondrial isolation and quantification of substrate utilization.* Mitochondria was isolated from intrascapular BAT and the left lateral liver lobe. Mitochondrial protein concentration was determined with a bicinchoninic acid protein assay kit (BCA; Thermo Fisher Scientific) according to manufacturer's instructions. An XF Analyzer (Seahorse Bioscience) was used to measure bioenergetics in mitochondria isolated from BAT and liver. Briefly, XF24 extracellular flux assay cartridge (Seahorse Bioscience) was hydrated overnight at 37°C according to manufacturer's instruction. Isolated mitochondria (6  $\mu$ g per well for BAT and 10  $\mu$ g per well for liver) were plated in MAS-1 buffer supplemented with 70 mM sucrose, 220 mM D-mannitol (MilliporeSigma), 5 mM potassium dihydrogen phosphate (Thermo Fisher Scientific), 5 mM magnesium chloride (MilliporeSigma), 2 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 1 mM EDTA (MilliporeSigma) and 0.2% fatty free acid BSA (MP Biologicals, pH 7.4) on a polyethylenimine (MilliporeSigma) precoated XF Cell Culture Microplate, centrifuged at 200 g for 12 minutes at 4°C, and incubated at 37°C in a non-CO<sub>2</sub> incubator for 10 minutes. Liver mitochondria were plated on an uncoated plate, centrifuged at 2,000 g for 20 minutes at 4°C, and incubated at 37°C in a non-CO<sub>2</sub> incubator for 10 minutes. For BAT, 3 mM sodium pyruvate/3 mM malate (MilliporeSigma), and 4  $\mu$ M FCCP (MilliporeSigma) were sequentially injected, and mitochondrial OCR was quantified. For liver, 5 mM succinate (MilliporeSigma) and 4  $\mu$ M FCCP were sequentially injected, and OCR was quantified.

*Analysis of mouse metabolic phenotypes.* Assessment of energy intake, energy expenditure, and home-cage activity were performed using an indirect calorimetric system (TSE PhenoMaster, TSE Systems). Data for energy expenditure were analyzed using analysis of covariance (ANCOVA) with body weight as covariant as previously described (59, 60). Briefly, mice were placed in calorimetric chambers that recorded oxygen consumption, as well as locomotor activity through use beam breaks.



*Flow cytometry.* Single cell suspensions were derived from hepatic and splenic homogenates. To determine immune cell populations, cells were labeled with monoclonal antibodies (all from eBioscience) at room temperature. For cytokine production, total single cells were stimulated for 4 hours with PMA (50 ng/ml; MilliporeSigma) and Ionomycin (1 µg/ml; Calbiochem) in presence of Brefeldin A (10 µg/ml; MilliporeSigma). Subsequently, data were collected using a LSR Fortessa (BD Biosciences) and analyzed using FlowJo X software (vX0.7). Briefly, cells were stained with Live/Dead stain (Zombie UV Dye, BioLegend, catalog 423107) and with directly conjugated monoclonal antibodies to CD45 (clone 104, BioLegend, catalog 109845), CD11b (clone M1/70, catalog 12-0112-81), F4/80 (clone BM8, catalog 17-4801-82), Gr1 (clone RB6-8C5, catalog 56-5931-82), NK1.1 (clone PK136, catalog 25-5941-82), TCRB (clone H57-597, catalog 47-5961-82), CD4 (clone GK1.5, catalog 11-0042-85), CD8 (clone 53-6.7, catalog 48-0081-82), IL-17A (clone 17B7, catalog 45-7177-82), IFN-γ (clone XMG1.2, catalog 25-7311-82), and FOXP3 (clone FJK-16s, catalog 17-5773-82) (all from eBioscience).

*RNA sequencing and gene expression quantification.* Gene expression was determined by running 50 bp single-end reads (~20 million reads per sample). All analysis was performed in Cufflinks 1.3.0, TopHat 1.4.0, and GeneSpring 7.0. Single-end 50-bp reads were aligned to the mouse genome (mm9) in TopHat v1.4.0. Following alignment, transcripts were quantified following the protocol described (61). Functional enrichments of differentially expressed genes were assessed through ToppGene, with a *P* value cutoff of 0.05. All original microarray data were deposited in the NCBI's Gene Expression Omnibus database (GEO GSE89626).

*Tri-one dimensional thin layer chromatography (TOD-TLC) analysis of neutral lipids from liver.* Acox1<sup>Lampel</sup> and WT control liver tissue (0.1 mg) from mice fed chow and HFHCD were homogenized in PBS, and cellular lipids were extracted into chloroform/methanol. Subsequently, lipid samples were evaporated using a nitrogen stream and a 52°C water bath and loaded onto high-performance thin layer chromatography plates precoated with silica gel 60 (Thermo Fisher Scientific). Plates were washed with chloroform and methanol to remove any contaminants, dried overnight at 120°C, and developed in a solvent system modified from a previous report (62). Briefly, plates were initially developed in a solvent mixture of chloroform/methanol/ acetic acid (90:10:1) up to 3 cm of a 10-centimeter plate and then dried and placed in a second solvent of hexane/diethyl ether/acetone (60:40:5) up to 8 cm of the plate. Next, plates were dried again and placed in a third solvent of hexane/diethyl ether (97:3) up to 9.5 cm of the plate. Finally, plates were placed in the final solvent of pure hexane, and the final solvent was run to the top of the plate. Bands were visualized by spraying with a 0.05% solution of primuline in acetone and water (80:20) and detected as ultraviolet spots at 366 nm on a Typhoon 9500 molecular imager (62).

*qPCR.* Tissue samples were homogenized in TRIzol. RNA was extracted, reverse transcribed to complementary DNA (cDNA), and subjected to qPCR analysis (Light Cycler 480 II; Roche Diagnostics) as previously described (14, 16). The primer sequences, all from Invitrogen are as follows: *Ccl2* forward, 5' - AGAT-GCAGTTAACGCCCCAC - 3', and reverse, 5' - TGTCTGGACCCATTCCTTCTTG - 3'; *Ccl3* forward, 5' - ACCATGACACTCTGCAACCAAG - 3', and reverse, 5' - TTGGAGTCAGCGCAGATCTG - 3'; *Ccl4* forward, 5' - TCTCTCCTCTTGCTCGTGGC - 3', and reverse, 5' - GAATACCACAGCTGGCTTGG - 3'; *Cxcl10* forward, 5' - CCTATGGCCCTCATTCTCAC - 3', and reverse, 5' - CGTCATTTTCTGCCT-CATCC - 3'; *Ccl22* forward, 5' - TGGAGTAGCTTCTTACCCA - 3', and reverse, 5' - TCTGGACCT-CAAAATCCTGC - 3'; *Ucp1* forward, 5' - TCAGCTGTTCAAAGCACACA - 3', and reverse, 5' - GTAC-CAAGCTGTGCGATGTC - 3'; *Igf1* forward, 5' - TCCTCTGTCATCTCTGGGCT - 3', and reverse, 5' - TGTGTACCAGAACCTGCTGC - 3'; *Fabp5* forward, 5' - TGTTGTTGCCATCACACGTA - 3', and reverse, 5' - AGGATCTCGAAGGGAAGTGG - 3'; *Spp1* forward, 5' - ATTTGCTTTTGCCTGTTTGG - 3', and reverse, 5' - GGACACCTCACTGAATGGCT - 3'; *H19* forward, 5' - CAACATCCCACCCAC-CGTAA - 3', and reverse, 5' - GCTCACCAAGAAGGCTGGAT - 3'; *Afp* forward, 5' - TCTTTCCACTC-CACTTTGGC - 3', and reverse, 5' - GGCGATGGGTGTTTAGAAAG - 3'; *Lipe* forward, 5' - TCTC-GTTGCGTTTGTAGTGC - 3', and reverse, 5' - ACGCTACACAAAGGCTGCTT - 3'; *Pnpla2* forward, 5' - GTTGAAGGAGGGATGCAGAG - 3', and reverse, 5' - GCCACTCACATCTACGGAGC - 3'; *Srebp1c* forward, 5' - CTGTCTACCCCCAGCATAG - 3', and reverse, 5' - GATGTGCGAACTGGACACAG - 3'; *Ppara* forward, 5' - CATGGGGAGAGAGGACAGA - 3', and reverse 5' - AGTTCGGGAACAAGAC-GTTG - 3'; and *Bactin* forward, 5' - GGCCCAGAGCAAGAGAGGTA - 3', and reverse, 5' - GGTTGG-CCTTAGGTTTCAGG - 3'.

*Statistics.* For statistical analysis, a normal distribution was assumed and parametric tests were employed. A 2-tailed student's *t* test was used when the comparison was between 2 groups, while a 1-way

ANOVA with Tukey's post hoc test to assess differences between specific groups was employed for 3 or more groups. Statistical analysis was completed using Prism 5a (GraphPad Software Inc.). All values are represented as means  $\pm$  SEM. A *P* value less than 0.05 was considered significant. For determination of sample size, an online statistical tool was utilized (<https://www.dssresearch.com/KnowledgeCenter/toolkitcalculators/statisticalpowercalculators.aspx>).

*Study approval.* All studies were performed in accordance with the procedures outlined in the *Guide for the Care and Use of Laboratory Animals* (National Academies Press, 2011) and approved by the CCHMC Institutional Animal Care and Use Committee (IACUC).

### Author contributions

MEMF, DAG, TES, RS, MC, RM, KL, AS, JPB, and SD participated in data generation. RS, RK, CS, AS, SPH, JPB, BJA, KH, and SD participated in analysis and interpretation of data. MEMF, DAG, KH, and SD participated in the conception and design of the study, obtained the funding, and wrote the manuscript. All authors have reviewed the manuscript and approve the final version.

### Acknowledgments

This study was supported, in part, by NIH R01DK099222 (to SD); R01DK099222-02S1 (associated with SD and MEMF); AHA 17POST33650045 (to MEMF); NIH T32AI118697 (associated with DAG); and PHS grant P30 DK078392 Pathology of the Digestive Disease Research Core Center at CCHMC (associated with SD). We thank Calvin C. Chan, Matthew J. Lawson, and Vishakha Sharma for technical assistance.

Address correspondence to: Senad Divanovic, Division of Immunobiology, Cincinnati Children's Hospital Medical Center, TCHRF - Location S, Room #S.5.405, 3333 Burnet Avenue, Cincinnati, Ohio 45229-3039, USA. Phone: 513.636.0286; Email: [senad.divanovic@cchmc.org](mailto:senad.divanovic@cchmc.org).

DAG's present address is: La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA.

MC's present address is: Divisions of Neonatology and Developmental Biology, David Geffen School of Medicine at UCLA, Mattel Children's Hospital UCLA, CA, USA.

AS's present address is: Department of Biology, Miami University, OH, USA.

- Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. *J Clin Invest.* 2008;118(9):2992–3002.
- Strissel KJ, et al. Adipocyte death, adipose tissue remodeling, and obesity complications. *Diabetes.* 2007;56(12):2910–2918.
- Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. *J Clin Invest.* 2003;112(12):1796–1808.
- Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. *Annu Rev Pathol.* 2010;5:145–171.
- Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. *Science.* 2011;332(6037):1519–1523.
- Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. *Am J Gastroenterol.* 2008;103(4):1036–1042.
- Jia L, et al. Hepatocyte Toll-like receptor 4 regulates obesity-induced inflammation and insulin resistance. *Nat Commun.* 2014;5:3878.
- Li L, et al. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. *Hepatology.* 2011;54(5):1620–1630.
- Giles DA, et al. Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling. *Nat Med.* 2017;23(7):829–838.
- Sharifnia T, et al. Hepatic TLR4 signaling in obese NAFLD. *Am J Physiol Gastrointest Liver Physiol.* 2015;309(4):G270–G278.
- Miele L, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. *Hepatology.* 2009;49(6):1877–1887.
- Mehal WZ. The Gordian Knot of dysbiosis, obesity and NAFLD. *Nat Rev Gastroenterol Hepatol.* 2013;10(11):637–644.
- Mills KH. TLR-dependent T cell activation in autoimmunity. *Nat Rev Immunol.* 2011;11(12):807–822.
- Harley IT, et al. IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. *Hepatology.* 2014;59(5):1830–1839.
- Giles DA, Moreno-Fernandez ME, Divanovic S. IL-17 Axis Driven Inflammation in Non-Alcoholic Fatty Liver Disease Progression. *Curr Drug Targets.* 2015;16(12):1315–1323.
- Giles DA, et al. Regulation of Inflammation by IL-17A and IL-17F Modulates Non-Alcoholic Fatty Liver Disease Pathogenesis. *PLoS ONE.* 2016;11(2):e0149783.

17. Gu FM, et al. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. *Mol Cancer*. 2011;10:150.
18. Liao R, et al. High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma. *J Exp Clin Cancer Res*. 2013;32:3.
19. Schröder T, et al. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis. *Mol Metab*. 2016;5 (4):283–295.
20. Postic C, Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. *Diabetes Metab*. 2008;34 (6 Pt 2):643–648.
21. Berson A, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. *Gastroenterology*. 1998;114 (4):764–774.
22. Averill MM, Bornfeldt KE. Lipids versus glucose in inflammation and the pathogenesis of macrovascular disease in diabetes. *Curr Diab Rep*. 2009;9 (1):18–25.
23. Laine PS, et al. Palmitic acid induces IP-10 expression in human macrophages via NF-kappaB activation. *Biochem Biophys Res Commun*. 2007;358 (1):150–155.
24. de Lima-Salgado TM, Alba-Loureiro TC, do Nascimento CS, Nunes MT, Curi R. Molecular mechanisms by which saturated fatty acids modulate TNF- $\alpha$  expression in mouse macrophage lineage. *Cell Biochem Biophys*. 2011;59 (2):89–97.
25. El Hajj HI, et al. The inflammatory response in acyl-CoA oxidase 1 deficiency (pseudoneonatal adrenoleukodystrophy). *Endocrinology*. 2012;153 (6):2568–2575.
26. Meyer K, Jia Y, Cao WQ, Kashireddy P, Rao MS. Expression of peroxisome proliferator-activated receptor alpha, and PPAR-Ralpha regulated genes in spontaneously developed hepatocellular carcinomas in fatty acyl-CoA oxidase null mice. *Int J Oncol*. 2002;21 (6):1175–1180.
27. Stauber AJ, et al. Constitutive expression of peroxisome proliferator-activated receptor alpha-regulated genes in dwarf mice. *Mol Pharmacol*. 2005;67 (3):681–694.
28. Poll-The BT, et al. A new peroxisomal disorder with enlarged peroxisomes and a specific deficiency of acyl-CoA oxidase (pseudo-neonatal adrenoleukodystrophy). *Am J Hum Genet*. 1988;42 (3):422–434.
29. Sheridan R, et al. Lampe1: an ENU-germline mutation causing spontaneous hepatosteatosis identified through targeted exon-enrichment and next-generation sequencing. *PLoS One*. 2011;6 (7):e21979.
30. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (\*). *Annu Rev Immunol*. 2010;28:445–489.
31. Passos ST, Silver JS, O'Hara AC, Sehy D, Stumhofer JS, Hunter CA. IL-6 promotes NK cell production of IL-17 during toxoplasmosis. *J Immunol*. 2010;184 (4):1776–1783.
32. Goodier MR, Londei M. Lipopolysaccharide stimulates the proliferation of human CD56+CD3- NK cells: a regulatory role of monocytes and IL-10. *J Immunol*. 2000;165 (1):139–147.
33. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. *J Exp Med*. 2002;195 (3):327–333.
34. González-Muniesa P, Milagro FI, Campión J, Martínez JA. Reduction in energy efficiency induced by expression of the uncoupling protein, UCP1, in mouse liver mitochondria. *Int J Mol Med*. 2006;17 (4):591–597.
35. Townsend KL, Tseng YH. Brown fat fuel utilization and thermogenesis. *Trends Endocrinol Metab*. 2014;25 (4):168–177.
36. Wenfeng Z, Yakun W, Di M, Jianping G, Chuanxin W, Chun H. Kupffer cells: increasingly significant role in nonalcoholic fatty liver disease. *Ann Hepatol*. 2014;13 (5):489–495.
37. Kawano Y, Nishiumi S, Saito M, Yano Y, Azuma T, Yoshida M. Identification of Lipid Species Linked to the Progression of Non-Alcoholic Fatty Liver Disease. *Curr Drug Targets*. 2015;16 (12):1293–1300.
38. Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. *Curr Pharm Des*. 2013;19 (29):5250–5269.
39. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. *Semin Cancer Biol*. 2004;14 (6):433–439.
40. Coussens LM, Werb Z. Inflammation and cancer. *Nature*. 2002;420(6917):860–867.
41. Bishayee A. The role of inflammation and liver cancer. *Adv Exp Med Biol*. 2014;816:401–435.
42. Day CP. From fat to inflammation. *Gastroenterology*. 2006;130(1):207–210.
43. Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. *Biomark Res*. 2013;1 (1):10.
44. Fan CY, Pan J, Usuda N, Yeldandi AV, Rao MS, Reddy JK. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. *J Biol Chem*. 1998;273 (25):15639–15645.
45. Reddy JK. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. *Am J Physiol Gastrointest Liver Physiol*. 2001;281(6):G1333–G1339.
46. Pyper SR, Viswakarma N, Yu S, Reddy JK. PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. *Nucl Recept Signal*. 2010;8:e002.
47. Cypess AM, Kahn CR. Brown fat as a therapy for obesity and diabetes. *Curr Opin Endocrinol Diabetes Obes*. 2010;17 (2):143–149.
48. Huang J, et al. Sustained activation of PPAR $\alpha$  by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice. *FASEB J*. 2012;26 (2):628–638.
49. Gaublotte JT, et al. Single-Cell Genomics Unveils Critical Regulators of Th17 Cell Pathogenicity. *Cell*. 2015;163 (6):1400–1412.
50. Bertola A, et al. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. *PLoS One*. 2010;5 (10):e13577.
51. Vonghia L, et al. Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features. *PLoS One*. 2015;10 (11):e0143380.
52. Gomes AL, et al. Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma. *Cancer Cell*. 2016;30 (1):161–175.
53. van der Windt GJ, et al. CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. *Proc Natl Acad Sci USA*. 2013;110 (35):14336–14341.
54. Ahmed M, Gaffen SL. IL-17 inhibits adipogenesis in part via C/EBP $\alpha$ , PPAR $\gamma$  and Krüppel-like factors. *Cytokine*. 2013;61

- (3):898–905.
55. Huang TT, et al. Genetic modifiers of the phenotype of mice deficient in mitochondrial superoxide dismutase. *Hum Mol Genet.* 2006;15 (7):1187–1194.
56. Kohli R, et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. *Hepatology.* 2010;52 (3):934–944.
57. Finkelman F, Morris S, Orekhova T, Sehy D. The in vivo cytokine capture assay for measurement of cytokine production in the mouse. *Curr Protoc Immunol.* 2003;Chapter 6:Unit 6.28.
58. Divanovic S, et al. Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. *J Infect Dis.* 2012;205 (1):152–161.
59. Tschöp MH, et al. A guide to analysis of mouse energy metabolism. *Nat Methods.* 2011;9(1):57–63.
60. Stemmer K, et al. Thermoneutral housing is a critical factor for immune function and diet-induced obesity in C57BL/6 nude mice. *Int J Obes (Lond).* 2015;39 (5):791–797.
61. Trapnell C, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc.* 2012;7 (3):562–578.
62. White T, Bursten S, Federighi D, Lewis RA, Nudelman E. High-resolution separation and quantification of neutral lipid and phospholipid species in mammalian cells and sera by multi-one-dimensional thin-layer chromatography. *Anal Biochem.* 1998;258 (1):109–117.